AQST
Aquestive Therapeutics, Inc.
4.07
+
0.14
3.56%
18 x 4.06
18 x 4.09
bid
ask
18 @ 04:00 PM
3.97-0.10 (2.46%)
Bearish
10
Bullish
37
sentiment
3.97
day range
4.25
1.27
52 week range
6.09
Prev Close3.93
Open3.98
Low3.97
High4.25
Volume1.95M
Avg. Volume2.56M
Market Cap366.17M
Inst. Own34.16%
Beta2.91
Short Ratio1.22
Div & Yield0.00 /
EPS-0.13
P/E0.00
1yr Target9.00
50day MA4.11
200day MA2.45
CNQ.TO
Canadian Natural Resources Limited
106.52
04:00 PM
+
0.84
0.79%
G.TO
Augusta Gold Corp.
0.96
03:59 PM
-
0.07
6.80%
AAA.AX
BetaShares Australian High Interest Cash ETF
50.25
02:10 AM
+
0.01
0.02%
ACC.NS
ACC Limited
2533.05
05:59 AM
-
46.55
1.80%
600690.SS
Haier Smart Home Co., Ltd.
28.35
03:00 AM
-
0.08
0.28%
0700.HK
Tencent Holdings Limited
348.40
04:08 AM
+
9.00
2.65%
1101.TW
Taiwan Cement Corp.
31.80
01:30 AM
-
0.20
0.62%
20MICRONS.NS
20 Microns Limited
162.85
05:59 AM
+
5.90
3.76%
Day Gain | ||
Gain | ||
Market Val | ||
Costs | ||
Cash | ||
Portfolio | ||
Realized | ||
Dividend |
News
...
Profile
...
Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder. Its proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; KYNMOBI, a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease; and Exservan, an oral soluble film formulation of riluzole for the treatment of amyotrophic lateral sclerosis. The company's proprietary pipeline of complex molecule product includes AQST-108, a sublingual film formulation delivering systemic epinephrine for the treatment of conditions other than anaphylaxis; and Anaphylm, an epinephrine sublingual film for the emergency treatment of allergic reactions, including anaphylaxis. In addition, it develops Adrenaverse, an epinephrine prodrug platform. The company was incorporated in 2004 and is headquartered in Warren, New Jersey.
Earning
...
Date | For | Estimate | Reported | Surprise | surprise % |
---|---|---|---|---|---|
2024-05-07 | 2024-03 | -0.09 | N/A | N/A | N/A |
2024-03-05 | 2023-12 | -0.08 | -0.12 | -0.04 | -50.00% |
2023-11-06 | 2023-09 | -0.11 | -0.03 | 0.08 | 72.73% |
2023-11-06 | 2023-09 | -0.11 | N/A | N/A | N/A |
2023-08-07 | 2023-06 | -0.11 | N/A | N/A | N/A |
2023-08-07 | 2023-06 | -0.11 | -0.1 | 0.01 | 9.09% |
Upgrade / Downgrade
...
Date | Firm | Action | From | To |
---|---|---|---|---|
2023-10-09 | Wedbush | Upgrade | Outperform | Outperform |
2023-10-09 | HC Wainwright & Co. | Upgrade | Buy | Buy |
2023-09-21 | Wedbush | Upgrade | Outperform | Outperform |
2023-09-21 | HC Wainwright & Co. | Upgrade | Buy | Buy |
2023-09-20 | JMP Securities | Upgrade | Market Outperform | Market Outperform |
2023-07-30 | HC Wainwright & Co. | Upgrade | Buy | Buy |
Insider Holder
...
Date | Name | Relation | Quantity | Description |
---|---|---|---|---|
2024-03-06 | BARBER DANIEL | Chief Executive Officer | 883.30K | Stock Award(Grant) |
2024-03-06 | BOYD PETER E | Officer | 246.00K | Stock Award(Grant) |
2024-03-06 | BRAENDER LORI J | General Counsel | 323.76K | Stock Award(Grant) |
2024-03-06 | JUNG CASSIE | Officer | 249.23K | Stock Award(Grant) |
2021-08-25 | KENDALL KEITH J. | Chief Executive Officer | 637.15K | Stock Gift |
2024-03-06 | KRAUS CARL N | Officer | 262.50K | Stock Award(Grant) |
Institution Ownership
...
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Bratton Capital Management, LP | 9.81M | 16.19M | 14.70% |
2023-06-29 | Vanguard Group Inc | 1.56M | 2.57M | 2.34% |
2023-06-29 | Renaissance Technologies, LLC | 1.23M | 2.03M | 1.84% |
2023-06-29 | Armistice Capital, LLC | 1.16M | 1.91M | 1.74% |
2023-09-29 | Vahanian & Associates Financial Planning Inc. | 722.11K | 1.10M | 1.08% |
2023-06-29 | Bracebridge Capital, LLC | 428.57K | 707.14K | 0.64% |
Fund Ownership
...
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Vanguard Total Stock Market Index Fund | 932.70K | 1.54M | 1.40% |
2023-06-29 | Vanguard Extended Market Index Fund | 493.68K | 814.56K | 0.74% |
2023-05-30 | Fidelity Extended Market Index Fund | 197.28K | 455.72K | 0.30% |
2023-06-29 | Bridgeway Funds Inc-Ultra Small Company Market Fund | 142.36K | 234.89K | 0.21% |
2023-08-30 | iShares Micro Cap ETF | 92.79K | 152.17K | 0.14% |
2023-05-30 | Fidelity Total Market Index Fund | 78.34K | 180.97K | 0.12% |
This topic has been deleted. Only users with topic management privileges can see it.
-
-
-
-
-
-
-
-
-
-
-
Offering diluting shares right before phase 3 release. Is it telling us something? Their phase 3 did not meet the endpoints. If I was them, I will offer diluting shares after phase 3 public. Investors will give me more money because they know my company is worth to invest.
-
You said this is phase 3, right? If it is good, why do they need more money for clinical trials (diluting shares offering)? I think 70% it is not good out come as they want it to be. Therefore, they need more money to conduct another study.
-
-
-
-
-
-
-
-
Aquestive (AQST) to Report Q2 Earnings: What's in Store?
news.google.com •